177 related articles for article (PubMed ID: 11850282)
1. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Alvarez J; Picazo JJ;
Antimicrob Agents Chemother; 2002 Mar; 46(3):892-5. PubMed ID: 11850282
[TBL] [Abstract][Full Text] [Related]
2. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
3. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Gales AC; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
Garrison MW; Mutters R; Dowzicky MJ
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 2000 Oct; 44(10):2747-51. PubMed ID: 10991855
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Waites KB; Duffy LB; Dowzicky MJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3479-84. PubMed ID: 17005838
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Mendes RE; Jones RN
Int J Antimicrob Agents; 2016 Aug; 48(2):144-50. PubMed ID: 27291285
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
Mayne D; Dowzicky MJ
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
